Loading
JBI-802 is a small-molecule inhibitor from Jubilant Therapeutics Inc., in registered phase 2 trials for myeloproliferative neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms.
JBI-802 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Jubilant Therapeutics Inc., in myeloproliferative neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms. Described in the registry record as a corest inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a corest inhibitor; the trial entries below carry the sponsor's wording.
1.JBI-802 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JBI-802" OR ABSTRACT:"JBI-802") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JBI-802, not a curated reading list.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and the tags pipeline, registry-only.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and the tags pipeline, registry-only.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.